By Kathleen Doheny Soon after Merck announced on October 1 that it would ask federal regulators for emergency use authorization (EUA) for its auspicious new COVID-19 pill, the accolades began. Former US Food and Drug Administration (FDA) chief Scott...
Merck’s recent announcement about Molnupiravir indicates the possible imminence of an orally administered antiviral medication targeting COVID-19. The market for this drug class is substantial, given that about 90% of COVID-19 patients fall in the mild-to-moderate...
— But enrollment halted early, and few patients were actually hospitalized by Molly Walker Remdesivir (Veklury) reduced risk of hospitalizations by 87% compared with placebo in outpatients at high risk of progression to severe COVID-19, a researcher said. While the...
By JoNel Aleccia Within a day of testing positive for covid-19 in June, Miranda Kelly was sick enough to be scared. At 44, with diabetes and high blood pressure, Kelly, a certified nursing assistant, was having trouble breathing, symptoms serious enough to send her to...
Championed by doctors and conservative radio hosts alike, monoclonal antibodies for Covid are in high demand — even from those who don’t want a vaccine. By Benjamin Mueller Lanson Jones did not think that the coronavirus would come for him. An avid tennis player in...
Dexamethasone Many doctors, including those in the United States, have been treating very ill COVID-19 patients with corticosteroids since the pandemic began. It makes biologic sense for those patients who have developed a hyper-immune response (a cytokine storm) to...
by Deep Shukla Acute respiratory distress syndrome (ARDS) is a potentially fatal condition involving lung damage, and experts often associate it with severe COVID-19.There is a link between high mortality rates and COVID-19-induced ARDS, which is why there is an...
By Gilmar Reis, et al. PREPRINT August 23, 2021 ABSTRACT Background Recent evidence indicates a potential therapeutic role of fluvoxamine for COVID-19. In the TOGETHER randomized platform clinical trial for acutely symptomatic patients with COVID-19, we assessed...
TrialSite has written extensively about the need for antiviral-type, early-care treatments targeting COVID-19. Early in the pandemic, this platform tracked numerous studies involving repurposed drugs such as ivermectin, favipiravir, hydroxychloroquine, and more. By...
Solidarity PLUS trial for promising drugs will roll out in 52 countries, an unprecedented global collaboration for COVID-19 R&D The World Health Organization (WHO) has announced the next phase in its Solidarity trial: Solidarity PLUS will enroll hospitalized...
A multinational, multi-site team of researchers led by Peter Jüni of St. Michael’s Hospital and the University of Toronto in Canada investigated the efficacy of heparin as a treatment for moderate to severe SARS-CoV-2 infection, the virus behind the COVID-19 pandemic....
Combining tocilizumab and sarilumab along with corticosteroids reduced the risk of death by 17% compared with corticosteroids alone. CIDRAP: WHO Advises 2 Monoclonal Antibodies For Severe COVID The World Health Organization (WHO) today recommended the use of...
TrialSite has emphasized the importance of research in the fight against COVID-19 and many other infectious diseases and other threats to humanity. Recently, researchers from the Tokyo University of Science (along with scientists from the National Institute of...
June 13, 2021 ~ TrialSite News Japanese-Led Team’s Preclinical Research Indicate Huge Potential for the Repurposed Drug Combo of Cepharanthine/Nelfinavir to Destroy COVID-19 A team of researchers from Japan, America, and the United Kingdom recently launched a study to...
June 1, 2021 ~ Trial Site News Indian Giant Reliance Industries Developing Niclosamide-based Drug Targeting COVID-19 Much like Ivermectin, Niclosamide is in the anthelmintic family of drugs, and recently, Indian mega-corporation Reliance Industries Ltd....